Our Pipeline

We are advancing the science and our approach through the following programs.

Program
Indication
Discovery
Validation
IND Enabling
Clinical

SBT-77-7101

Sonoma Solomark Fullcolor Rgb 72A novel regulatory T cell-based therapy in development for the treatment of rheumatoid arthritis and hidradenitis suppurativa.

An autologous (using the patient’s own cells) Treg cell therapy to target proteins in the inflamed, disease-associated tissue, with the aim to dampen inflammation and restore balance to the immune system.

 

Regeneron-Partnered Programs

Engineered regulatory T cell-based therapeutics for patients with IBD and other diseases.

In partnership with:

Regeron Logo R

Includes programs previously under the Sonoma Bio 7200 series.
To learn more about our partnership with Regeneron, read our Press Release.

SBT-11-5301

Sonoma Solomark Fullcolor Rgb 72An effector T Cell-modulating biologic for autoimmune diseases.

SBT-11-5301 is a biologic designed to eliminate highly activated effector T cells (Teff) that are dominant in autoimmune and inflammatory disease.

Istock 1189303727 Aspect Ratio 1559 1413

Partnerships

We are always looking for the right academic and industry partners.